Neuphoria Therapeutics Inc. (NEUP) Stock Price & Analysis
Neuphoria Therapeutics Inc. (NEUP) closed at USD 3.31 on Thursday, October 15, 2026, up 2.16% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 3.31; the Oct 15, 2026 session ranged USD 3.25–3.42 on volume of 18,748 shares. Market capitalization is —, with a 52-week range of USD 3.19–17.19 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NEUP.md
Key facts (NEUP)
- Analysts: Hold (mean 3.00 on a 1–5 scale) (1 analysts).
- Total return with dividends: 1Y -78.2% vs S&P 500 +18.1%; 5Y -97.9% vs S&P 500 +85.1%.
Analysts (NEUP)
Consensus Hold (mean 3.00 on a 1–5 scale), 1 analysts.
Total return (dividends reinvested) (NEUP)
| 1Y (from 2025-10-16) | 5Y (from 2021-12-13) | |
|---|---|---|
| Total return | -78.2% | -97.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -78.3% | -54.9% |
| Volatility (annualized) | 139.6% | 119.7% |
| Max drawdown | -79.1% (Oct 2025→Oct 2026) | -98.5% (Dec 2021→Oct 2024) |
Key Statistics (as of October 16, 2026 at 05:11 UTC)
| Price | USD 3.31 |
|---|---|
| Change | ▲ 2.16% (up) |
| Previous Close | USD 3.31 |
| Open | USD 3.31 |
| Day Range | USD 3.25 – 3.42 |
| 52-Week Range | USD 3.19 – 17.19 |
| Volume | 18,748 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (NEUP)
Nexqual's technical model rates NEUP "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:11 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 30.54 (neutral) |
| vs SMA50 | Below (USD 3.69) |
| MACD | -0.12 (negative) |
Analyst Ratings (NEUP)
Wall Street analysts rate NEUP "Hold" based on 1 analysts, per Nexqual as of October 16, 2026 at 05:11 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 1 |
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (NEUP)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.26 vs est -0.56 ▲ beat |
| 2026-03-31 | USD -0.09 vs est -0.56 ▲ beat |
| 2025-12-31 | USD 0.41 vs est -0.56 ▲ beat |
| 2025-09-30 | USD -4.41 vs est -1.31 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financials & Fundamentals (NEUP)
| Total Revenue | $1.17M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -15.66% |
| Profit Margin | +0.00% |
| ROE | -61.70% |
| Debt / Equity | 0 |
| Current Ratio | 27.85 |
| Total Cash | $19.87M |
| Total Debt | $34,345 |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financial Health Score (NEUP)
Nexqual rates Neuphoria Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:11 UTC.
| Growth | Critical — Revenue -93% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $20M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$12M (FY ended Jun 2026, 10-K) |
| Efficiency | Critical — ROE -62%, ROA -19.7% |
Ownership (NEUP)
| Insider Ownership | +5.02% |
|---|---|
| Institutional Ownership | +43.34% |
| Shares Outstanding | 5.41M |
| Float | 5.37M |
| Short % of Float | +0.45% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Leadership (NEUP)
Neuphoria Therapeutics Inc. is led by Spyridon Papapetropoulos (age 52), Interim CEO & Executive Director, per Nexqual as of October 16, 2026 at 05:11 UTC.
| Interim CEO & Executive Director | Spyridon Papapetropoulos (age 52) |
|---|---|
| Fractional CFO | Timothy M. Cunningham (age 63) |
| Senior Vice President of Business Operations | Julie Kerner |
Major Backers & Investors (NEUP)
Notable institutional backers of Neuphoria Therapeutics Inc. include Lynx1 Capital Management Lp, AdvisorShares Trust-AdvisorShares Psychedelics ETF, AdvisorShares Investments, LLC, according to Nexqual as of October 16, 2026 at 05:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Lynx1 Capital Management Lp | 16.18% |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 5.78% |
| AdvisorShares Investments, LLC | 4.67% |
| Shay Capital LLC | 2.88% |
| Balyasny Asset Management LP | 2.63% |
| Citadel | 1.34% |
| Fidelity | 0.99% |
| Ikarian Capital, LLC | 0.88% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.04% |
| Geode Capital | 0.92% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt